leverage real-world evidence and patient engagement to ... · pdf fileregister today by...

Eric Tse, General Manager, Shire Pharmaceutical

Take Away Key Strategies on:

New Critical Regulatory Changes

Public and Private Payer Strategies

Real-world Evidence

Improved Patient Outcomes

Biosimilars and Orphan Drugs

New Launch Planning

Health Technology Assessment Process

Meet + Network + Learn From:

www.MarketAccessCanada.ca

Gold Sponsors: Bronze Sponsor:Silver Sponsor:

2 In-depth Workshops:

A: Price Listing Agreements

B: Pharmacist Engagement

Leverage Real-world Evidence and Patient Engagement to Reduce Listing Time

Monday, November 13th & Tuesday, November 14th, 2017 Arcadian Court | Toronto, ON

Strategy Institute presents...

Imran Ali, Senior Manager, pan-Canadian Pharmaceutical Alliance Office (pCPA)

Mitch Moneo, Acting Assistant Deputy Minister, BC Ministry of Health

Karen Voin, Assistant Vice President – Group Benefits and Anti-fraud, Canadian Life and Health Insurance Association

Tanya Potashnik, Director, Policy & Economic Analysis Branch, Patented Medicine Prices Review Board (PMPRB)

Deborah Maskens, Founder, Kidney Cancer Canada

8+ Public & Private Payers speaking!

AHS, BC Health, QC Health, CLHIA, Blue Cross, and More!

Breakfast Sponsor:

Register Today by calling 1-866-298-9343 x 200

Welcome to the Longest-running and Most

Thoughtful Market Access Event in Canada.

This prestigious gathering of top leaders in the pharmaceutical

industry will provide you with fresh insights from government,

private payers, patients, employers, and drug access networks.

Leverage real world evidence and stakeholder partnerships to

reduce costs and delays in listing.

With more pressure on prices, your market access strategy is

crucial to speed up access to treatments and reimbursement. Stay

up to date with changes in the industry to better strategize your

submissions and improve your decision-making.

Make sure your organization is on the cutting edge of market

access practice. Effectively deliver benefits for both your bottom

line and the health care system!

Sincerely,

Your Market Access Team

Strategy Institute

New for this year!

Perspective from Regional Health authorities

Address specific demographics

Gain a better overview with twice as many panels

Focused sessions within tracks

Analyze the impact of drug access navigators

Meet + Network + Learn from:

Event in Numbers

Update from Health Canada

2 days

7 panels

25+ speaker

3 patient advocacy groups

1 amazing conference experience

6 private and public payers

5 tracks

2

REGISTER TODAY!Get all the updates you need on Market Access in Canada. Save your spot now for Canada’s largest conversation on HTA, formulary listings and patient outcomes.

1-866-298-9343 ext 200

[email protected]


START THE CONVERSATION BEFORE THE SUMMIT!

Spread the word and engage in the debate by tweeting your thoughts using #MarketAccess17 or follow @MarketAccessCA.

Join the Canadian Pharmaceuticals: Legislative Demand, Regulations, Market Access & Reimbursement Network, and share your views with our growing group members.

Who You Will Meet

Take away 10 exclusive insights on:

1. Payer-specific Submissions: Customize your application

to the payers’ priorities

2. Regulatory Update: Understand upcoming updates to

PMPRB and pCPA policies

3. HTA Process: Strategize your submissions to reduce delays

4. New Launches: Increase the ROI of your R&D

5. Real-world Evidence: Integrate data to boost your

value proposition

6. Biosimilars: Stay at the forefront of upcoming drug markets

7. Stakeholder Engagement: Create partnerships to better

answer the demand patients and payers

8. Specialized Drugs: Access to treatment for rare diseases

9. Companion Diagnostic: Adapt to new CDR guidelines

10. Global Trends: Align your national strategy with global trends

Register Today at www.MarketAccessCanada.ca

Past Attendees Include

Astellas Pharma ■ Astra Zeneca ■ Bayshore Healthcare ■ Biogen Canada ■ Boehringer-Ingelheim ■ Eli Lilly Canada ■ Galderma Canada ■ Gilead Sciences Canada ■ GlaxoSmithKline ■ Hoffmann-La Roche ■ Janssen ■ Manulife Financial ■ Merck Canada ■ Novartis Pharmaceuticals Canada ■ Otsuka Pharmaceuticals ■ Pfizer Canada ■ Pfizer Canada ■ Roche ■

Servier Canada ■ Teva Canada

Directors | Managers | Drug Plan Management | Formulary Listing | Reimbursement and Pricing Programs| Public Affairs | Senior Pharmacist | Senior Policy Analysts

• Converse directly with your target audience

• Present changes and announcements on a national platform

• Evaluate industry sentiment

Presidents | Vice Presidents | Managing Partners | Principals | Business Development Officers | Sales and Account Managers | Managers/Directors of Marketing/Sales

• Expand your network of industry stakeholders

• Determine opportunities for future business

• Demonstrate your leadership in the industry

Directors and Managers | Group Benefits | Group Benefit Advisors | Pharmacy Services | Drug Plan Management

• Outline industry challenges and find collaborative solutions

• Explore new programs and initiatives

• Engage with industry stakeholders

Pharmaceutical manufacturers

Vice President | Director and Managers of Market Access | External Relations | Government Relations | Public Affairs | Pricing and Reimbursement

• Improve submission success rates

• Track industry updates and regulatory changes

• Adapt to cost-cutting measures

Private payers and plan developers

Provincial, federal and government regulators

Insights & analytics, pricing & reimbursement consulting, public affairs and public relations consulting, patient support services, technology consulting, law firms

Join Linkedin Canadian Pharmaceuticals: Market Access and Reimbursement Network

Monday November 13th, 2017DAY ONE

9:00 AM Panel Discussion: RWE

Adopt Innovative Solutions in the Use of Real-world Evidence to Enhance your Decision-makingGovernments, payers and healthcare’s other stakeholders increasingly look to incorporate data to support decision-making. Explore innovation in Real-World Evidence to improve the value, efficacy and impact of medicines. Take away strategies to:

• Enhance efficacy of your medicines on individual patient outcomes• Evaluate the impact on the health of the overall populations• Partner with your stakeholders to access data

Prove and improve the value, efficacy and impact of your medicines with RWE.

Neil Corner, General Manager - Real World Insight, QuintilesIMS

7:30 AM Registration and Breakfast

8:15 AM Opening Comments From the Chair

Kaitlyn Proulx, Managing Director,PDCI

10:15 AM Morning Break

8:30 AM Keynote Address: PMPRB

Assess Regulatory Changes to Determine Their Impact on Your Market Access StrategyPMPRB Framework modernization is underway with significant changes pending to both the Patented Medicine’s Regulations and PMPRB Pricing Guidelines. Gather insights on:

• The latest developments on Health Canada’s proposal to add new factors to the PMPRB’s price ceiling setting process

• How the PMPRB might operationalize these factors as part of its new risk-based approach to price regulation

Discover what regulatory changes can mean to your market access strategy.

Tanya Potashnik, Director, Policy & Economic Analysis Branch,Patented Medicine Price Review Board

9:45 AM Health Canada

Improve Access to Necessary Therapeutic ProductsThe Regulatory Review of Drugs and Devices (R2D2) initiative is underway. Review the objectives of this initiative to improve access to treatment. Stay up-to-date on:

• Expanded collaboration with health partners• More timely access to drugs and devices• Enhanced use of real word data

Analyze the R2D2 initiative to bolster access to treatment.

Michèle Chadwick, Lead, Regulatory Review of Drugs and Devices, Health Canada

10:45 AM Panel Discussion: Oncology drug HTA

Assess Stakeholders’ Perspectives on HTA Process to Improve Your SubmissionsWith pCODR review and possible re-review, patients can wait 2 to 4 years for access to innovative cancer treatments. Advance your submission strategy to include broader stakeholder insights. Source intelligence to:

• Review current HTA processes, timelines, potential delays • Understand the new patient and clinician input processes to pCODR• Assess the impact of provincial re-review and pCODR Request for

Advice (RFA) on access

Review the effect of all stakeholder submissions to better strategize your market access strategy.

Deborah Maskens, Founder, Kidney Cancer Canada

Laurene Redding, Independent

12:30 PM Networking Lunch

1:00 PM Lunch & LearnDriving Value Out of Upstream Data

Moderator

11:30 AM Patient Advocacy

Establish How you Can Help your Users to Optimize Access and AdherenceReconciling the urgency of patient need with a thorough HTA process is a growing a challenge. Explore what patients expect from you to improve patient outcomes. Gain insights to:

• Assess patient inputs in the evaluation of formularies• Refine your stakeholder mapping• Advance your stakeholder engagement process

Ensure the patients are at the centre of your strategic planning.

Lorna Warwick, National Director, Education & ServicesLymphoma Canada

12:00 PM Panel Discussion: Private Payers

Analyze Emerging Trends Among Private Payers and Adapt to ChangeThe private payer landscape is undergoing significant changes that will impact patient access and how medications are reimbursed. Strengthen your market access strategy with insights into emerging trends in the private payer landscape. Source critical information to:

• Assess trends among large employers • Revise changes in industry leadership and emerging partnerships• Review the solutions plan sponsors are considering

Integrate the employer’s outlook into your market access strategies.

Chris Goguen, Strategic Pharmaceutical Partnerships Lead, Medavie Blue Cross

Barbara Martinez Practice Leader, Benefits Solutions, The Great-West Life Assurance Company

Karen Voin, Assistant Vice President - Group Benefits and Anti-fraud, Canadian Life and Health Insurance Association

CHOOSE YOUR TRACKJoin your peers in sessions designed for specific types of drugs

COMMON DRUGS

1:30 PM Case Study: ODANO

Analyze ODANO’s Work with Patients to Anticipate the Demand Side of the Market ODANO is a new Ontarian drug access navigator to facilitate cancer drug coverage. Analyze the impact of drug access navigators on patients to increase speed of reimbursement. Gain insights on:

• Educating patients• Establishing and enhancing partnerships• Best practice sharing among patients

Explore what drug access navigators can do to increase the speed of reimbursement.

Alan Birch,Administrator, Drug Access Navigator of Ontario

SPECIALITY DRUGS – ONCOLOGY

2:00 PM Case Study: Managing Data

Structure your Data from Real-world Setting to Enhance your Value PropositionReal-world evidence can be a challenge due to the complexity of the data. Learn from Sanofi’s experience to strategize your data management. Gain practical tips to:

• Address specific patient outcomes within your researches• Analyze the impact of RWE on your submission• Review your value proposition

Gain practical insights on the challenges of RWE from Sanofi’s experience.

Karine Alloul, Senior Manager, Health Economics and Health Outcomes, Sanofi

2:00 PM Oncology Biosimilars

Market Access considerations for BiosimilarsThe next wave of biosimilars is about to enter the Canadian market and present unique issues not part of the current landscape. Learn about the considerations associated with institutionally-based products such as oncology monoclonal antibodies, including:

• Pharmaceutical policy related to reimbursement• Regulatory review, naming convention, health technology

assessment, and public funding• Key differences related to levels of evidence, switching and

funding mechanisms

Assess the considerations for Oncology biosimilars.

Heather Francis, Director of Healthcare and Innovation, Roche Canada

2:30 PM Industry Expert

Implications of Global Trends on Pharmaceutical Pricing and Reimbursement in Canada International price referencing has always influenced the reimbursable price. Assess how international developments, specifically the Canada-EU Trade Agreement, will impact Canada’s P&R. Source critical information on:

• Evolution of HTA in Europe • Formal and informal cooperation between HTA agencies • Risk sharing, listing agreements

Track the evolution of European pricing and listing regimes and assess their implications for your market.

2:30 PM Industry Expert

Turning Policy into Action to Achieve your Patient Access Goals Demands on more value for healthcare dollars are driving policy and systems-wide changes. Ensure you play a role in enabling patient access and quality of care. Sources strategies to:

• Build an integrated patient access strategy • Motivate decision-makers to keep the cost to the patients in mind • Integrate digital advocacy into your plans

Strategize and plan accordingly to get the attention of market access decision-makers.


3:00 PM Afternoon Break

1:30 PM Case Study: New Product Pricing

Increase Patient Access with Differential Pricing ConsiderationsIn a highly regulated pricing market pharmaceutical companies look to incorporate differential pricing domestically to increase patient access. Review how to approach Canadian “differential pricing” to increase patient access. Gain insights to:

• Analyze how price impact patient’s ability to choose a product that best meets her/his needs

• Price your products while addressing changing market expectations

• Increase access to priority products with portfolio pricing in different markets

Join us for a timely and stimulating discussion that will inform your pricing strategy development for future launch products.

Rosemarie Childerhose, Lead, Patient Relations and Government Relations, Valeant Pharmaceuticals

PLENARY SESSIONS CONTINUE

Follow us on Twitter @MarketAccessCA, #MarketAccessCA

Tuesday November 14th, 2017DAY TWO

4:00 PM Panel Discussion: Companion Diagnostic Tests

Anticipate a Need to Include Relevant Companion Diagnostics Tests with Your New Drug SubmissionsCDR guideline are likely to change and major lab diagnostic testing companies and patient support programs are pro-acting for this eventuality. Adapt to changing CDR guidelines and Improve your submissions with companion diagnostic tests. Source intelligence to:

• Highlight changes to CDR• Discuss commercialization of companion diagnostics• Review how payers intend to integrate these requirements into

their coverage plans

Strengthen your new submission with relevant companion diagnostic tests.

Greg Rutherford, Director - Pharmaceutical Solutions, McKesson Canada

Christopher Trevors, National Director - Genetic Health Solutions, Dynacare

John Anacleto,Director of Payer Relations,McKesson Canada

10:00 AM Panel: Quebec’s Market

Everything You Always Wanted to Know about Quebec’s Market Access but Afraid to Ask!Since the 2014 general election, the Quebec Government has shown the desire to proceed with major cut backs in the healthcare system. Wide-ranging reforms, aimed at conclusively fixing Quebec’s health system, are impacting service providers, manufacturers, healthcare professionals, and patients. Explore how your organization can position itself in this turbulent time. Master the success factors to:

• Understand the regulatory framework in place and the policy environment

• Explore future issues and challenges• List your projects in the government’s vision

Get an update on the government’s vision to navigate a fast changing regulatory landscape.

Alain Madgin,Senior Vice President,Citoyen Optimum

+ More to come

3:30 PM Regional Health Authority

Assess the National Formulary Collaborative (NFC) from the Perspective of Alberta’s Regional Health Authority Regional health authorities are working to improve alignment with public drug plans and utilize the best available evidence when reviewing hospital only drugs. Analyze the NFC and the hospital formulary review process in Alberta to improve your market access strategy. Gain insights to:

• Review NFC, its purpose and its impact on manufacturers and payers

• Comprehend policy alignment with CADTH and Alberta Drug Benefit List

• Provide an overview of the formulary review process in Alberta and the challenges for coverage

Evaluate the evolution of decision-making at the regional level and its effects on your organization.

Jeremy Slobodan, Director, Drug Utilization, Information & Stewardship, Alberta Health Services

5:25 PM Conference Adjourns to Day Two

5:30 PM Executive Evening Reception

4:45 PM Afternoon Keynote: British Columbia Update

Align your Strategy with Payer Policies to Increase the Speed of ReimbursementWith long negotiations and shrinking budgets, patients are likely to wait longer to get reimbursed. Stay in tune with payer priorities to ensure that your patients are quickly reimbursed. Develop your action plan to:

• Clarify coverage criteria• Define and demonstrate value to the payers• Advance your listing agreements

Adapt your value proposition to ensure the coverage of your treatments.

Mitch Moneo, Acting Assistant Deputy Minister, BC Ministry of Health

Eric Lun, Executive Director – Drug Intelligence Optimization, BC Ministry of Health

9:30 AM Panel: Data Insights

Advance Evidence Generation to Improve your Organization’s Access to MarketThe trends occurring in the public and private plan designs are essential to developing your market access strategy. Leverage data insights within the patient support program environment to move from a reimbursement focus to an evidence generation focus. Discover insights to:

• Link plan design with patient access • How patient support programs can generate Real World Evidence

in decision making• Identify the trends that affect different products

Analyze how the changing reimbursement landscape is impacting market access to optimize your company’s access strategies.

Alison Drinkwater, Senior Director Strategic Consulting,Innomar Strategies

7:00 AM Registration and Breakfast

8:15 AM Opening Comments From the Chair

John-Paul Dowson, Managing Director, Roubaix Strategies

8:30 AM Keynote: pCPA Update

Review pCPA Approach to Negotiation and Pricing to Prepare your Submissions BetterThe pCPA changed notably in the past few years and its approach to negotiation has evolved. Reassess your expectation and improve your submissions. Source Intelligence to:

• Enhance the use of your company’s research and marketing resources

• Improve consistency of decisions and achieve lower drug costs• Facilitate communication between your company, the federal

government and the provinces

Review changes at pCPA to enhance your submission process.

Imran Ali,Senior Manager,pCPA


10:45 AM Morning Break

11:45 AM Case Study: R&D Alliance Support Growth in Your Early Stage Pipeline to Improve Access to TreatmentsCollaboration is a crucial aspect of R&D and early stage of new product launches. Ensure a successful launch for your new products and advance access to treatments. Gain insights to:

• Advance your transfer of technology• Strengthen your R&D collaborations• Demonstrate the value of your new products

Bolster your product development and make innovative health treatment available on the market.

Amyn Sayani,Interim Director - Health Economics and Outcomes Research & Specialty Pharmaceuticals, Medical Affairs, GSK

COMMON DRUGS

11:45 AM Case Study: Orphan Drugs

Collaborate with Stakeholders to Develop your Products and Improve Patient OutcomesSmall markets can impede the development of orphan drugs, but collaboration can alleviate some restraints. Build partnerships to develop your new products and secure revenue opportunities. Build a roadmap to:

• Explore funding and joint research opportunities• Gather inputs from patients• Optimize your company’s ROI in a small market

Work with your stakeholders to increase patient access to treatments.

Eric Tse,General Manager, Shire Pharmaceutical

SPECIALITY DRUGS – RARE DISEASES

12:15 PM Industry Expert: Patient Access

Improve your Uptake and Adherence with Effective Patient Support ServicesSpecialty support programs in Canada help patients navigate healthcare insurance and reimbursement processes. Understand how to design and implement customized program solutions to help patients gain access to your specialty medication without delay. Source critical insights to:

• Gain access to reimbursement assistance programs• Assure your programming adherence and compliance• Integrate clinical and logistic services to improve your

patient’s experience

Support patients’ journeys with better access to treatments.

12:15 PM Industry Expert: Pricing

Anticipate Pressure on Price to Reduce Delays in the Listing of your High Price DrugsAlthough speciality drugs represent 5% of prescriptions, they represent 20–25% of the benefits paid. Review your pricing strategy to reduce delays in listing.

• Improve your HEOR• Develop your pricing strategy for three-tiered drug plans• Anticipate demand side for your new patients

Plan your negotiation strategy to streamline listing of your high priced drugs.

CHOOSE YOUR TRACKJoin your peers in sessions designed for specific types of drugs

12:45 PM Networking Lunch

11:15 AM CDR Update

Evaluate CDR’s Priority to Minimize Delays in your SubmissionsCADTH CDR made changes to improve transparency and HTA timelines. Explore what these changes can do to streamline your submissions. Source intelligence on:

• New advanced notifications for expedited Health Canada Review• Closer partnerships between CDR and pCPA• Changes in the 4th HTA guidelines

Align with new CDR guidelines to advance your approval processes.

Senior Manager,CADTH


1:45 PM Employer Perspective

Encourage Sponsors to Cover Your Drug and Ascertain How They Can Be Incorporated into Your Access StrategyPrivate sponsors need a clear value-proposition to enhance their benefit plans. Clarify your value proposition to ensure employees access to the best treatments. Gain practical insights to:

• Align your treatments with wellness programs • Promote cost-reduction strategies that go beyond

generic substitution • Address short-comings of stepped drug plans

Include sponsor insights in your value proposition to increase patient access to treatments.

GENERIC DRUGS

1:45 PM Payer Partnerships

Optimize your Access When Negotiating With Group Purchasing OrganizationsThe growing transparency at CADTH and shrinking hospital budgets are changing the perspective of GPOs. Adapt to GPO’s approach to ensure your access to hospital and community care. Create a roadmap to:

• Analyze the work of hospital review boards within GPOs• Clarify purchase criteria • Address cost concerns

Work with your stakeholders to increase patient access to treatments.

Doug Nanton, Market Access & Government Affairs – Western Canada & Ottawa, Valeant Canada

BRAND DRUGS

2:15 PM Case Study: Competitive Value Price Initiative

Reduce your Drug Costs to Secure Access the Generic Drugs MarketThe Pan-Canadian Competitive Value Price Initiative for Generic Drugs reduces the price by 15–18% of the brand price. Protect your market access by adapting to lower drug prices. Build a roadmap to:

• Identify product impacted by the initiative• Review updates on the initiative• Adjust your public payer strategy

Overcome the challenges of shrinking drug prices to enhance market access.

2:15 PM Case Study: Global Price and Market Access

Refine your Global Negotiation Strategy to Optimize your AccessAdapting a global pricing strategy to Canadian markets continues to be a challenge. Work efficiently with global affiliates and Canadian payers to improve your negotiations. Source insights to:

• Involve your global pricing team• Tailor your value proposition• Advance your marketing strategy

Enhance your commercialization planning in a global context.

Nadia Turchetta, Executive Director, Biopharmaceuticals, Sandoz

CHOOSE YOUR TRACK

PLENARY SESSIONS CONTINUE

3:30 PM Conference Adjourns

2:45 PM Panel: Biosimilars

Update on Biologic Regulatory Approval Processes to Ensure your Responsive Access StrategyHealth Canada released its revised guidance document on the approval pathway for biosimilars in December 2016. Review the new guidance to optimize your access to market. Take away new ideas to:

• Assess new options for biosimilar drugs• Prepare your clinical and non-clinical information• Strengthen your risk-management plans

Explore what the new Health Canada guidance means to you

Nadia Turchetta Executive Director, Biopharmaceuticals, Sandoz

+ More to come


One of Toronto’s most sought after, this event complex boasts historic charm and modern sophistication in its two distinct venues – the revitalized Arcadian Court and the new Arcadian Loft – and offers interactive experiences in its kitchen studio – Arcadian Studio.

The grand Arcadian Court has been restored to its art deco glory featuring modern new amenities, while a flexible contemporary space has also been created in Arcadian Loft. Together, these two spaces form a unique venue, which will meet the needs of any event or occasion. Arcadian’s maximum seated capacity is 800 and its standing capacity is 1,500.

Location: Arcadian Court, 401 Bay Street, Simpson Tower, 9th Floor, Toronto, ON, M5H 2Y4

POST CONFERENCE WORKSHOP

9:00 AM - 12:00 PM

Drive Successful pCPA Strategies and PLAs to Solidify your Market Access Strategies The pan-Canadian Pharmaceutical Alliance (pCPA) has established their office and become a formal process for getting new drugs to the market. Source insights to manage and optimize your submission. Tap into both public and private perspectives in this interactive workshop and walk away with knowledge to:

1. Understand the pCPA process and submissions

2. Prepare for pCPA in the planning stages of your products

3. Use pricing models to assist your product’s positioning during negotiations

4. Gain an understanding of different types of Canadian PLAs

5. Take advantage of potential opportunities in private sector PLAs

Develop your successful pCPA strategy through this hands-on interactive workshop.

Colin Vicente, Managing Director, Pivina

1:00 PM - 4:00 PM

Create a Holistic Market Access Strategy that Includes Pharmacists to Add Value to your Patients’ JourneysPharmacists in a majority of provinces are now allowed to prescribe medication, adjust dosages, extend prescriptions, and administer drugs by injection. Evaluate the impact of these changes on your market access strategy. Determine how you can engage pharmacists and improve your relationship with patients at the same time. Develop an actionable roadmap that will:

1. Deliver insights into pharmacists’ expanded scope of practice and evolving business models

2. Give you actionable strategies to engage with pharmacists and pharmacy operators

3. Identify opportunities to increase patient access

4. Offer new opportunities for tracking patient behaviour and outcomes

5. Increase adherence

Integrate pharmacists into your market growth strategy.

Wednesday, November 15th 2017

(416) 364-1211 | 1.888.244.6656

Your Conference Venue!

WORKSHOP A

Price Listing Agreement

WORKSHOP B

Pharmacist Engagement

https://www.oliverbonacinievents.com/Venues/Arcadian.aspx

4

5 67

89

3

21

Thought Leadership Room

Exhibit Room

Networking

SOLD SOLD

SOLD

Who you will meet...

DON’T MISS THIS OPPORTUNITY TO BE AT THE CENTRE OF THE ACTION!

To learn more, contact Jason Entine at 1-866-298-9343 ext. 272 or email [email protected]

Connect with world leading Market Access practitioners. Find answers to your biggest challenges!

EVENT SPONSORSHIP OPPORTUNITIES AT CANADA’S LARGEST MARKET ACCESS SUMMIT The is the longest-running market access event in Canada, drawing delegates from leading pharmaceutical organizations, public and private payers and regulatory bodies. Take advantage of keynote sessions, case studies and panels to initiate thoughtful conversations with leaders.

TOP 5 REASONS TO SPONSOR

1. Meet hundreds of delegates who have market access as a top priority.

2. Join the largest and longest-running market access event in Canada.

3. Establish your thought leadership in market access.

4. Promote your products and service offering.

5. Gather intelligence and forge key relationships.

*Limited exhibit space and sponsorship packages are available.

50% Managers

28% VP & Director

22% Senior Managers

Attendee Title Breakdown



Monday, November 13th & Tuesday, November 14th, 2017 Arcadian Court | Toronto, ON

Learn from pCPA, PMPBR and Health Canada

ATTENTION MAILROOM: If undeliverable to addressee, please forward to: Directors/Managers of Market Access, Pricing, Reimbursement, External Affairs, Government Affairs, Submissions, Regulatory Affairs, Patient Access, Stakeholder Engagement

Registration fee: Subject to 13% HST. The Regular investment includes luncheon, refreshments, networking breaks, continental breakfast, and original course materials. Payment is required in advance and can be made by company cheque, VISA, MasterCard, or American Express. Please make cheques payable to Strategy Institute Inc.

Early Bird special: Expires on September 1st & October 13th, 2017. Cannot be used with group discount.

Group Discount: A Group Discount is offered for this conference (not in combination with any other offer). To be eligible for the Group Discount, delegates MUST register at the same time. The total discount per delegate (including applicable group discounts, etc.) MUST not exceed 25% of the regular conference costs.

Cancellations: Must be received in writing by October 30th, 2017. You will be eligible for a prompt refund less a $495.00 administrative fee. If you register for the program and do not attend, you are liable for the full registration fee unless you cancel according to the terms stated above. If you are unable to attend, delegate substitution is permitted up to, and including, the day of the conference.

Admission Policy: Strategy Institute reserves the right to restrict entry to the conference to any individual. Any such person requested to leave the conference site shall do so immediately upon request, whether previously issued a badge permitting entry. There is no refund payable with respect to anyone refused entry. Any information obtained at the conference cannot be relied upon for any particular set of circumstances, cannot be taken as professional advice or opinion. Attendees must consult with the appropriate professional before acting in response to information obtained at the conference.

Evening Social Activities: Please drink responsibly. Strategy Institute shall not be liable for any consequential damages and/or personal injuries caused by excessive or irresponsible alcohol consumption.

4 EASY WAYS TO REGISTER

Tel: 1-866-298-9343 ext. 200 Email: [email protected] Web: www.marketaccesscanada.caMail: Strategy Institute, 401 Richmond St. West, Suite 401 Toronto, Ontario M5V 3A8

Conference only $2,195 $2,795

Conference + 1 Workshop $2,690 $3,290

Conference + 2 Workshops $2,985 $3,585

RegularVendors,

Suppliers, Consultants SAVE $400Register by Sept 1st

SAVE $200Register by Oct 13th

GROUP BOOKINGS: RECEIVE 25% DISCOUNT. REGISTER FOUR DELEGATES AND EACH PERSON WILL RECEIVE A 25% DISCOUNT

CONFERENCE CODE: 117025Workshops Only $595 - EACH

Acquire Critical Insights from:

leverage real-world evidence and patient engagement to ... · pdf fileregister today by...

Documents